London, UK-based Arix Bioscience has entered into a strategic agreement with French drugmaker Ipsen to develop and commercialise innovative therapies.
The deal gives Ipsen access to Arix’ network of professional and scientific advisors, and the chance to invest in the firm’s new and existing businesses.
In return, Ipsen will contribute research, development and commercial expertise to the partnership.
The parties will work together on identifying opportunities and jointly create new companies focused primarily on the development and commercialisation of innovative therapies for patients.
Arix sources, finances and builds healthcare and life science businesses addressing medical innovation at all stages of development.
The firm made investments into 13 innovative life science companies in 2016 and 2017, with “multiple value-creating milestones” expected over the next 18 months.